GANCICLOVIR (DHPG) FOR SYMPTOMATIC CONGENITAL CYTOMEGALOVIRUS INFECTIONS

更昔洛韦 (DHPG) 治疗有症状的先天性巨细胞病毒感染

• 批准号: 6112846
• 负责人: RICHARD J. WHITLEY
• 金额: $ 2.95万
• 依托单位: UNIVERSITY OF ALABAMA AT BIRMINGHAM
• 依托单位国家: 美国
• 财政年份: 1998
• 资助国家: 美国
• 起止时间: 1998-12-01 至 1999-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6112846
• 关键词: Herpesviridae disease; acute disease /disorder; central nervous system disorders; child (0-11); clinical research; congenital infection; cytomegalovirus; ganciclovir; growth /development; hearing; human subject; human therapy evaluation; infant human (0-1 year); microorganism disease chemotherapy; outcomes research; virus load; vision

This is a randomized, controlled trial to evalute the efficacy of treatment with DHPG (12mg/kg/day) Vs. no treatment in neonates with symptomatic congenital cytomegalovirus and CNS disease. Only babies with symptomatic congenital infection who stand to derive therapeutic benefit are eligible for the study.

这是一项随机对照试验，旨在评估 DHPG（12 毫克/公斤/天）与 DHPG 治疗的疗效。患有症状性先天性巨细胞病毒和中枢神经系统疾病的新生儿无需治疗。 只有患有先天性感染症状并能获得治疗益处的婴儿才有资格参加该研究。